Related Experiment Video
Updated: Mar 7, 2026

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Sudden visual loss after cardiac resynchronization therapy device implantation
Luigi A De Vitis1, Alessandro Marchese1, Chiara Giuffrè1
1Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute, Milan - Italy.
Insights
Sudden vision loss after cardiac resynchronization therapy (CRT) may stem from cardiogenic embolism, potentially linked to infective endocarditis. This case highlights a rare complication impacting visual acuity post-CRT device implantation.
Area of Science:
- Ophthalmology
- Cardiology
- Neurology
Background:
- Cardiac resynchronization therapy (CRT) is a treatment for heart failure.
- Complications following CRT device implantation can occur, though visual disturbances are rare.
Observation:
- A 62-year-old man experienced sudden monocular vision loss after CRT implantation.
- Ophthalmologic examination revealed Roth spots and delayed retinal perfusion on fluorescein angiography.
- The patient later suffered an ischemic stroke following a temporal artery biopsy.
Findings:
- The visual acuity loss was attributed to a possible cardiogenic embolism, potentially from undiagnosed infective endocarditis.
- Despite inflammatory signs improving on angiography, visual acuity did not recover.
- The mechanism of severe visual damage without significant retinal anatomical alteration remains unclear.
Implications:
- This case suggests a potential link between CRT, infective endocarditis, and embolic events causing vision loss.
- Further investigation into embolic phenomena following CRT is warranted.
- Ophthalmologists and cardiologists should consider embolic causes in patients presenting with vision loss post-CRT.
Purpose:
To report a case of sudden decrease in visual acuity possibly due to a cardiogenic embolism in a patient who underwent cardiac resynchronization therapy (CRT) device implantation.
Methods:
A 62-year-old man with severe left ventricular systolic dysfunction and a left bundle branch block was referred to our department because of a sudden decrease in visual acuity. Nine days earlier, he had undergone cardiac transapical implantation of a CRT device, which was followed, 2 days later, by an inflammatory reaction. The patient underwent several general and ophthalmologic examinations, including multimodal imaging.
Results:
At presentation, right eye (RE) best-corrected visual acuity (BCVA) was counting fingers and RE pupil was hyporeactive. Fundus examination revealed white-centered hemorrhagic dots suggestive of Roth spots. Fluorescein angiography showed delay in vascular perfusion during early stage, late hyperfluorescence of the macula and optic disk, and peripheral perivascular leakage. The first visual field test showed complete loss of vision RE and a normal left eye. Due to suspected giant cell arteritis, temporal artery biopsy was performed. Thirty minutes after the procedure, an ischemic stroke with right hemisyndrome and aphasia occurred. The RE BCVA worsened to hands motion. Four months later, RE BCVA did not improve, despite improvement in fluorescein angiography inflammatory sign.
Conclusions:
We report a possible cardiogenic embolism secondary to undiagnosed infective endocarditis causing monocular visual loss after CRT device implantation. It remains unclear how the embolus caused severe functional damage without altering the retinal anatomical structure.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
16:40A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiopulmonary Resuscitation III: AED Use
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiac Catheterization IV: Nursing Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy